Clinical Trial: NCT03721172
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Amgen |
| Information Provided By: | Amgen |
| Last Update Posted: | 2024-05-29 |
Study Overview
Brief Summary
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.
Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.
Official Title
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis
Conditions
Psoriasis
Intervention / Treatment
- Drug: Apremilast
- Other: Placebo
Other Study ID Numbers
- CC-10004-PSOR-022
- U1111-1218-8372
Start Date (Actual)
2019-03-11
Primary Completion Date (Actual)
2020-03-06
Study Completion Date (Actual)
2020-07-24
Enrollment (Actual)
595
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Amgen |
| Information Provided By: | Amgen |
| Last Update Posted: | 2024-05-29 |
Study Overview
Brief Summary
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.
Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.
Official Title
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis
Conditions
Psoriasis
Intervention / Treatment
- Drug: Apremilast
- Other: Placebo
Other Study ID Numbers
- CC-10004-PSOR-022
- U1111-1218-8372
Start Date (Actual)
2019-03-11
Primary Completion Date (Actual)
2020-03-06
Study Completion Date (Actual)
2020-07-24
Enrollment (Actual)
595
Study Type
Interventional
Phase
Phase 3